FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 935 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Oncolytic Virus Enables the Immune System to Attack Tumors October 12, 2023 Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... November 24, 2025 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung... August 5, 2021 Load more HOT NEWS ‘Will cancer make me infertile?’ – That Cancer Conversation Trial Suggests Expanded Role for Blinatumomab in Treating ALL Data from a Large Cohort of Patients with mRCC Demonstrate the... Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On...
